Neurochemical Research

, Volume 34, Issue 2, pp 379–385

Myc-oncogene Inactivating Effect by Proline Rich Polypeptide (PRP-1) in Chondrosarcoma JJ012 Cells

Original Paper

Abstract

Proline rich polypeptide (PRP-1) produced by NPV and NSO cells is released into the general circulation and exerts its effect on the activity of immunocompetent and neuronal cells. PRP-1 is a unique regulator of hematopoiesis, stimulator of bone-marrow hematogenesis. Taking into consideration our preliminary data on antitumor and unique diverse biological properties of PRP-1 previously described by Galoyan et al., we proceeded with investigation of the PRP-1 effect on chondrosarcoma, the second most common malignancy in bone, which tends to be locally invasive and then metastatic. Currently it does not have any effective treatment and does not respond either to radiation or chemotherapy, leaving surgical resection as the only option. Our experimental results of PRP-1 action on human chondrosarcoma JJ012 cells demonstrated inactivation, abolishment of Myc oncogene activity usually upregulated in chondrosarcoma cells and other malignancies. The fact that addition of PRP-1 caused drastic inactivation of Myc–luc response element to the control level in human chondrosarcoma JJ012 cell line prompts to investigate further this neuropeptides powerful antioncogenic potential, opening up possibilities to consider PRP-1 as a potential therapeutic tool for chondrosarcoma treatment.

Keywords

Proline rich polypeptide Chondrosarcoma Myc oncogene Hypothalamic neuropeptides Cancer 

References

  1. 1.
    Galoyan AA (2004) Brain neurosecretory cytokines: immune response and neuronal survival. Kluwer Academic/Plenum Publishers, NYGoogle Scholar
  2. 2.
    Galoyan AA (2008) The brain immune system: chemistry and biology of the signal molecules. In: Galoyan A, Besedovsky H (eds) Handbook of neurochemistry and molecular neurobiology, v.Neuroimmunology, Chap. 7, pp 155–195Google Scholar
  3. 3.
    Galoyan AA, Grigorian SL, Badalyan ChV (2006) Treatment and prophylaxis of anthrax by brain neurosecretory cytokines. Neurochem Res 31(6):795–803PubMedCrossRefGoogle Scholar
  4. 4.
    Galoyan AA, Sarkissian JS, Chavushyan VA et al (2005) Neuroprotective action of hypothalamic peptide PRP-1 at various time survival following spinal cord hemisection. Neurochem Res 30(4):507–525PubMedCrossRefGoogle Scholar
  5. 5.
    Galoyan AA (2000) Neurochemistry of brain neuroendocrine immune system: signal molecules. Neurochem Res 25(9/10):1343–1355PubMedCrossRefGoogle Scholar
  6. 6.
    Galoyan AA, Aprikyan VS (2002) A new hypothalamic polypeptide is a regulator of myelopoiesis. Neurochem Res 27(4):305–312PubMedCrossRefGoogle Scholar
  7. 7.
    Galoyan AA, Shirvanian AJu (2006) Patent N 1696 AGoogle Scholar
  8. 8.
    Simonyan GM, Nersesyan AK, Simonyan RM, Babayan MA, Simonyan MA, Galoyan AA (2005) Antitumor and antistressor effects of hypothalamic proline rich peptide (PRP-1) in sarcoma 45; possible biochemical mechanisms. Neurochemistry (RAS and NAS RA) 22(2):125–130Google Scholar
  9. 9.
    Galoyan AA, Shakhlamov VA, Kondakova LI, Altukhova VI, Polyakova GP (2001) The influence of proline-rich polypeptide on the morphology and mitotic activity of neurinoma Hassel node of tumor cells at rats (electron microscopic investigations). PNAS (Russian Academy of Sciences) 101(2):279–286Google Scholar
  10. 10.
    Galoyan AA, Shakhlamov VA, Malaytsev VV (2001) Changes in tumor cells L929 under PRP effect in vitro. Med Sci Armenia 41(1):25–29Google Scholar
  11. 11.
    Mirra J (1989) In: Lea and Febiger, bone tumors. PhiladelphiaGoogle Scholar
  12. 12.
    Frassica FJ, Unni KK, Beabout JW, Sim FH (1986) Dedifferentiated chondrosarcoma. A report of the clinicophathological features and treatment of seventy-eight cases. J Bone Joint Surg Am 68:1197–1205PubMedGoogle Scholar
  13. 13.
    Scully SP, Berend KR, Toth A, Qi WN, Qi Z, Block JA (2000) Marshall Urist Award. Interstitial collagenase gene expression correlates with in vitro invasion in human chondrosarcoma. Clin Orthop Relat Res 376:291–303PubMedCrossRefGoogle Scholar
  14. 14.
    Galoian KA, Garamszegi N, Garamszegi SP, Scully SP (2007) Molecular mechanism of tenascin-C action on matrix metalloproteinase-1 invasive potential. Exp Biol Med 232(4):515–522Google Scholar
  15. 15.
    Fong YC, Yang WH, Hsu SF, Hsu HC, Tseng KF, Hsu CJ, Lee CY, Scully SP (2007) Methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells. Orthop Res 25(8):1106–1114CrossRefGoogle Scholar
  16. 16.
    Sherf BA (1996) Dual luciferase reporter assay: an advanced coreporter technology integrating firefly and renilla luciferase assays. Promega Notes 57:2–9Google Scholar
  17. 17.
    Schally AV, Cumaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos (2001) Front Neuroendocrinol 22:248–291PubMedCrossRefGoogle Scholar
  18. 18.
    Shachaf CM, Felsher DW (2005) Tumor dormancy and Myc inactivation: pushing cancer to the brink of Normalcy. Cancer Res 65:4471–4474PubMedCrossRefGoogle Scholar
  19. 19.
    Bishop JM (1991) Molecular themes in oncogenesis. Cell 64:235–248PubMedCrossRefGoogle Scholar
  20. 20.
    Druker BJ, Sawyers CL, Kantarjian H et al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042PubMedCrossRefGoogle Scholar
  21. 21.
    Driker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031–1037CrossRefGoogle Scholar
  22. 22.
    Felsher DW, Nicole Bradon (2003) Pharmacological Inactivation of MYC for the treatment of cancer. Drug News Perspect 16(6):370–374PubMedCrossRefGoogle Scholar
  23. 23.
    Felsher DW (2003) Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer 3:375–378PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Department of Orthopedics, Miller School of MedicineUniversity of MiamiMiamiUSA
  2. 2.Department of Orthopedics, Miller School of MedicineUniversity of Miami HospitalMiamiUSA
  3. 3.Institute of BiochemistryNational Academy of SciencesYerevanRepublic of Armenia

Personalised recommendations